Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep694 | Pituitary and Neuroendocrinology | ECE2022

Evaluation of the effectiveness of patients with acromegaly treatment (according to the moscow register)

Antsiferov Mikhail , Alekseeva Tatiana , Pronin Evgenii , Ionova Olga , Goldman Elena , Orlova Ekaterina , Matosyan Karina

The aim: To determine the prognostic parameters affecting the course of acromegaly (A.) and the effectiveness of drug therapy (MT).Matherials and methods: 779 patients of A. [218 men (28%)] aged 60 (48/69) years, [Me(25%/75%)] were included in the Moscow register. The prevalence of A. in Moscow is 61.6; the incidence is 4.0 cases/million inhabitants. The treatment algorithm included surgical aid (495 patients), primary (I) or secondary (II) MT (584) and ...

ea0022p579 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

The prognostic criteria for the efficiency of the long-termed administration of somatostatin analogues

Pronin Vyacheslav , Gitel Eugeny , Vasilyeva Irina , Antsiferov Mikhail , Alexeeva Tatiana , Goldman Elena , Dorofeeva Olga

The efficiency of the prolonged medical therapy of acromegaly with the somatostatin analogues (SA) strictly correlates with the initial sensitivity to the drug. Before the onset of SA therapy 114 patients with acromegaly (35 men and 79 women) aged 54 (48/61) years old (Me (25/75%) underwent the test with Octreotide (Sandostatin®): 300 μg sc within 3 days. The decrease of IGF1 level positively correlated with the age of the acromegaly onset (r=0.38) and negativ...